282 related articles for article (PubMed ID: 7866432)
1. Farnesylation of p21 Ras proteins in Xenopus oocytes.
Zhao J; Kung HF; Manne V
Cell Mol Biol Res; 1994; 40(4):313-21. PubMed ID: 7866432
[TBL] [Abstract][Full Text] [Related]
2. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.
Manne V; Yan N; Carboni JM; Tuomari AV; Ricca CS; Brown JG; Andahazy ML; Schmidt RJ; Patel D; Zahler R
Oncogene; 1995 May; 10(9):1763-79. PubMed ID: 7753553
[TBL] [Abstract][Full Text] [Related]
3. A peptide from the GAP-binding domain of the ras-p21 protein and azatyrosine block ras-induced maturation of Xenopus oocytes.
Chung DL; Brandt-Rauf P; Murphy RB; Nishimura S; Yamaizumi Z; Weinstein IB; Pincus MR
Anticancer Res; 1991; 11(4):1373-8. PubMed ID: 1746893
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of farnesyl protein transferase by monoterpene, curcumin derivatives and gallotannin.
Chen X; Hasuma T; Yano Y; Yoshimata T; Morishima Y; Wang Y; Otani S
Anticancer Res; 1997; 17(4A):2555-64. PubMed ID: 9252680
[TBL] [Abstract][Full Text] [Related]
5. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.
Yan N; Ricca C; Fletcher J; Glover T; Seizinger BR; Manne V
Cancer Res; 1995 Aug; 55(16):3569-75. PubMed ID: 7627966
[TBL] [Abstract][Full Text] [Related]
6. Ras farnesyltransferase inhibition: a novel and safe approach for cancer chemotherapy.
Nammi S; Lodagala DS
Acta Pharmacol Sin; 2000 May; 21(5):396-404. PubMed ID: 11324435
[TBL] [Abstract][Full Text] [Related]
7. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line.
Ghosh PM; Ghosh-Choudhury N; Moyer ML; Mott GE; Thomas CA; Foster BA; Greenberg NM; Kreisberg JI
Oncogene; 1999 Jul; 18(28):4120-30. PubMed ID: 10435593
[TBL] [Abstract][Full Text] [Related]
8. Protein prenylation: key to ras function and cancer intervention?
Khosravi-Far R; Cox AD; Kato K; Der CJ
Cell Growth Differ; 1992 Jul; 3(7):461-9. PubMed ID: 1419908
[No Abstract] [Full Text] [Related]
9. Identification and preliminary characterization of protein-cysteine farnesyltransferase.
Manne V; Roberts D; Tobin A; O'Rourke E; De Virgilio M; Meyers C; Ahmed N; Kurz B; Resh M; Kung HF
Proc Natl Acad Sci U S A; 1990 Oct; 87(19):7541-5. PubMed ID: 2217184
[TBL] [Abstract][Full Text] [Related]
10. Prenylation of mammalian Ras protein in Xenopus oocytes.
Kim R; Rine J; Kim SH
Mol Cell Biol; 1990 Nov; 10(11):5945-9. PubMed ID: 2233726
[TBL] [Abstract][Full Text] [Related]
11. Farnesylation and proteolysis are sequential, but distinct steps in the CaaX box modification pathway.
Farh L; Mitchell DA; Deschenes RJ
Arch Biochem Biophys; 1995 Apr; 318(1):113-21. PubMed ID: 7726551
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships of cysteine-lacking pentapeptide derivatives that inhibit ras farnesyltransferase.
Leonard DM; Shuler KR; Poulter CJ; Eaton SR; Sawyer TK; Hodges JC; Su TZ; Scholten JD; Gowan RC; Sebolt-Leopold JS; Doherty AM
J Med Chem; 1997 Jan; 40(2):192-200. PubMed ID: 9003517
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of farnesyltransferase and Ras processing peptidase.
Hall CC; Watkins JD; Ferguson SB; Foley LH; Georgopapadakou NH
Biochem Biophys Res Commun; 1995 Dec; 217(3):728-32. PubMed ID: 8554591
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Xenopus laevis oocyte farnesyl transferase.
Goalstone ML; Diamond CL; Sadler SE
Biol Reprod; 1996 Mar; 54(3):675-81. PubMed ID: 8835391
[TBL] [Abstract][Full Text] [Related]
16. Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase.
Lingham RB; Silverman KC; Jayasuriya H; Kim BM; Amo SE; Wilson FR; Rew DJ; Schaber MD; Bergstrom JD; Koblan KS; Graham SL; Kohl NE; Gibbs JB; Singh SB
J Med Chem; 1998 Nov; 41(23):4492-501. PubMed ID: 9804689
[TBL] [Abstract][Full Text] [Related]
17. Geranylgeranyl as well as farnesyl moiety is transferred to Ras p21 overproduced in adrenocortical cells transformed by c-Ha-rasEJ oncogene.
Osman H; Mazet JL; Maume G; Maume BF
Biochem Biophys Res Commun; 1997 Feb; 231(3):789-92. PubMed ID: 9070894
[TBL] [Abstract][Full Text] [Related]
18. Farnesyl protein transferase inhibitors as potential cancer chemopreventives.
Kelloff GJ; Lubet RA; Fay JR; Steele VE; Boone CW; Crowell JA; Sigman CC
Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):267-82. PubMed ID: 9107432
[TBL] [Abstract][Full Text] [Related]
19. K-ras oncogene expression in Xenopus laevis.
Baum EZ; Bebernitz GA
Oncogene; 1990 May; 5(5):763-7. PubMed ID: 2189109
[TBL] [Abstract][Full Text] [Related]
20. Pathways for activation of the ras-oncogene-encoded p21 protein.
Pincus MR; Chung D; Dykes DC; Brandt-Rauf P; Weinstein IB; Yamaizumi Z; Nishimura S
Ann Clin Lab Sci; 1992; 22(5):323-42. PubMed ID: 1524403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
